{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T20:16:13Z","timestamp":1788380173511,"version":"build-2803163510"},"reference-count":49,"publisher":"American Society for Microbiology","issue":"3","license":[{"start":{"date-parts":[[2022,3,15]],"date-time":"2022-03-15T00:00:00Z","timestamp":1647302400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2022,3,15]],"date-time":"2022-03-15T00:00:00Z","timestamp":1647302400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"funder":[{"DOI":"10.13039\/100010877","name":"ViiV Healthcare","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010877","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2022,3,15]]},"abstract":"<jats:p>The FLAIR study demonstrated noninferiority of monthly long-acting cabotegravir + rilpivirine versus daily oral dolutegravir\/abacavir\/lamivudine for maintaining virologic suppression. Three participants who received long-acting therapy had confirmed virologic failure (CVF) at Week 48, and all had HIV-1 that was originally classified as subtype A1 and contained the baseline integrase polymorphism L74I; updated classification algorithms reclassified all 3 as HIV-1 subtype A6.<\/jats:p>","DOI":"10.1128\/aac.01702-21","type":"journal-article","created":{"date-parts":[[2022,1,3]],"date-time":"2022-01-03T18:19:59Z","timestamp":1641233999000},"update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":28,"title":["Impact of Integrase Sequences from HIV-1 Subtypes A6\/A1 on the\n            <i>In Vitro<\/i>\n            Potency of Cabotegravir or Rilpivirine"],"prefix":"10.1128","volume":"66","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5676-0437","authenticated-orcid":true,"given":"Jerry L.","family":"Jeffrey","sequence":"first","affiliation":[{"name":"ViiV Healthcare, Research Triangle Park, North Carolina, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marty","family":"St. Clair","sequence":"additional","affiliation":[{"name":"ViiV Healthcare, Research Triangle Park, North Carolina, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping","family":"Wang","sequence":"additional","affiliation":[{"name":"ViiV Healthcare, Research Triangle Park, North Carolina, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunfu","family":"Wang","sequence":"additional","affiliation":[{"name":"ViiV Healthcare, Branford, Connecticut, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhufang","family":"Li","sequence":"additional","affiliation":[{"name":"ViiV Healthcare, Branford, Connecticut, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jagadish","family":"Beloor","sequence":"additional","affiliation":[{"name":"ViiV Healthcare, Branford, Connecticut, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Talarico","sequence":"additional","affiliation":[{"name":"ViiV Healthcare, Research Triangle Park, North Carolina, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Fridell","sequence":"additional","affiliation":[{"name":"ViiV Healthcare, Branford, Connecticut, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8905-2584","authenticated-orcid":true,"given":"Mark","family":"Krystal","sequence":"additional","affiliation":[{"name":"ViiV Healthcare, Branford, Connecticut, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C. Thomas","family":"White","sequence":"additional","affiliation":[{"name":"ViiV Healthcare, Research Triangle Park, North Carolina, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandy","family":"Griffith","sequence":"additional","affiliation":[{"name":"ViiV Healthcare, Research Triangle Park, North Carolina, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald","family":"D\u2019Amico","sequence":"additional","affiliation":[{"name":"ViiV Healthcare, Research Triangle Park, North Carolina, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimberly","family":"Smith","sequence":"additional","affiliation":[{"name":"ViiV Healthcare, Research Triangle Park, North Carolina, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veerle","family":"Van Eygen","sequence":"additional","affiliation":[{"name":"Janssen Pharmaceutica NV, Beerse, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johan","family":"Vingerhoets","sequence":"additional","affiliation":[{"name":"Janssen Pharmaceutica NV, Beerse, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kati","family":"Vandermeulen","sequence":"additional","affiliation":[{"name":"Janssen Pharmaceutica NV, Beerse, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Spreen","sequence":"additional","affiliation":[{"name":"ViiV Healthcare, Research Triangle Park, North Carolina, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"van Lunzen","sequence":"additional","affiliation":[{"name":"ViiV Healthcare, Brentford, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1013911"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1086\/505147"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1002\/phar.2246"},{"key":"e_1_3_2_5_2","volume-title":"Update of recommendations on first- and second-line antiretroviral regimens (WHO\/CDS\/HIV\/19.15).","author":"World Health Organization","year":"2019","unstructured":"World Health Organization. 2019. Update of recommendations on first- and second-line antiretroviral regimens (WHO\/CDS\/HIV\/19.15). World Health Organization, Geneva, Switzerland."},{"key":"e_1_3_2_6_2","volume-title":"Guidelines: version 10.1.","author":"European AIDS Clinical Society","year":"2020","unstructured":"European AIDS Clinical Society. 2020. Guidelines: version 10.1. European AIDS Clinical Society, Brussels, Belgium."},{"key":"e_1_3_2_7_2","volume-title":"Guidelines for the use of antiretroviral agents in adults and adolescents with HIV.","author":"Panel on Antiretroviral Guidelines for Adults and Adolescents","year":"2021","unstructured":"Panel on Antiretroviral Guidelines for Adults and Adolescents. 2021. Guidelines for the use of antiretroviral agents in adults and adolescents with HIV. Rockville, MD, Department of Health and Human Services."},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.17025"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)60918-0"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)60917-9"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0708975"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)61853-4"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1215541"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)32340-1"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)32299-7"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3018(15)00027-2"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3018(17)30095-4"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.2147\/HIV.S145529"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(13)61221-0"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1089\/aid.2019.0171"},{"key":"e_1_3_2_21_2","first-page":"abstr 125","article-title":"Development of integrase inhibitor resistance under firstline treatment with bictegravir","author":"Braun P","year":"2020","unstructured":"Braun P, Wiesmann F, Naeth G, Knechten H, Stoll M. 2020. Development of integrase inhibitor resistance under firstline treatment with bictegravir. Abstr HIV Drug Therapy Glasgow 2020, abstr 125.","journal-title":"Abstr HIV Drug Therapy Glasgow 2020"},{"key":"e_1_3_2_22_2","first-page":"abstr P018","article-title":"Durable efficacy of dolutegravir (DTG) plus lamivudine (3TC) in antiretroviral treatment\u2013naive adults with HIV-1 infection\u20143-year results from the GEMINI studies","author":"Cahn P","year":"2020","unstructured":"Cahn P, Sierra Madero J, Arribas JR, Antinori A, Ortiz R, Clarke AE, Hung C-C, Rockstroh JK, Girard P-M, Sievers J, Man CY, Urbaityte R, Underwood M, Pappa KA, Smith KY, Gartland M, Aboud M, van Wyk J, Wynne B. 2020. Durable efficacy of dolutegravir (DTG) plus lamivudine (3TC) in antiretroviral treatment\u2013naive adults with HIV-1 infection\u20143-year results from the GEMINI studies. Abstr HIV Drug Therapy Glasgow 2020, abstr P018.","journal-title":"Abstr HIV Drug Therapy Glasgow 2020"},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1097\/COH.0000000000000002"},{"key":"e_1_3_2_24_2","volume-title":"Cabenuva prescribing information.","author":"ViiV Healthcare","year":"2021","unstructured":"ViiV Healthcare. 2021. Cabenuva prescribing information. ViiV Healthcare, Research Triangle Park, NC."},{"key":"e_1_3_2_25_2","volume-title":"Cabenuva product monograph.","author":"ViiV Healthcare ULC","year":"2021","unstructured":"ViiV Healthcare ULC. 2021. Cabenuva product monograph. ViiV Healthcare ULC, Laval, Quebec."},{"key":"e_1_3_2_26_2","volume-title":"Vocabria summary of product characteristics.","author":"ViiV Healthcare BV","year":"2021","unstructured":"ViiV Healthcare BV. 2021. Vocabria summary of product characteristics. ViiV Healthcare BV, Amersfoort, Netherlands."},{"key":"e_1_3_2_27_2","volume-title":"Rekambys summary of product characteristics.","author":"Janssen Pharmaceutica NV","year":"2021","unstructured":"Janssen Pharmaceutica NV. 2021. Rekambys summary of product characteristics. Janssen Pharmaceutica NV, Beerse, Belgium."},{"key":"e_1_3_2_28_2","volume-title":"Cabenuva product information.","author":"ViiV Healthcare Pty Ltd","year":"2021","unstructured":"ViiV Healthcare Pty Ltd. 2021. Cabenuva product information. ViiV Healthcare Pty Ltd, Abbotsford, Victoria."},{"key":"e_1_3_2_29_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1909512"},{"key":"e_1_3_2_30_2","first-page":"abstr 3957","article-title":"Long-acting cabotegravir + rilpivirine for HIV maintenance: FLAIR week 48 results","author":"Orkin C","year":"2019","unstructured":"Orkin C, Arasteh K, G\u00f3rgolas Hern\u00e1ndez-Mora M, Pokrovsky V, Overton ET, Girard P-M, Oka S, D'Amico R, Dorey D, Griffith S, Margolis DA, Williams P, Parys W, Spreen WR. 2019. Long-acting cabotegravir + rilpivirine for HIV maintenance: FLAIR week 48 results. Abstr Conference on Retroviruses and Opportunistic Infections, abstr 3957.","journal-title":"Abstr Conference on Retroviruses and Opportunistic Infections"},{"key":"e_1_3_2_31_2","doi-asserted-by":"publisher","DOI":"10.3390\/v12080838"},{"key":"e_1_3_2_32_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00984-08"},{"key":"e_1_3_2_33_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01345-09"},{"key":"e_1_3_2_34_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01209-10"},{"key":"e_1_3_2_35_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2008.06.012"},{"key":"e_1_3_2_36_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12977-018-0420-7"},{"key":"e_1_3_2_37_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0708978"},{"key":"e_1_3_2_38_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.00470-08"},{"key":"e_1_3_2_39_2","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000002883"},{"key":"e_1_3_2_40_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)32666-0"},{"key":"e_1_3_2_41_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1904398"},{"key":"e_1_3_2_42_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.03909-14"},{"key":"e_1_3_2_43_2","first-page":"abstr 2495","article-title":"Pharmacokinetics of cabotegravir and rilpivirine long-acting injectables in HIV-infected individuals through 48 weeks in the FLAIR and ATLAS phase 3 studies","author":"Patel P","year":"2019","unstructured":"Patel P, Ford SL, Crauwels H, Han K, Rossenu S, Neyens M, Lou Y, Griffith S, Hudson KJ, Margolis DA, Baker M, Williams PE, Spreen WR. 2019. Pharmacokinetics of cabotegravir and rilpivirine long-acting injectables in HIV-infected individuals through 48 weeks in the FLAIR and ATLAS phase 3 studies. Abstr IDWeek 2019, abstr 2495.","journal-title":"Abstr IDWeek 2019"},{"key":"e_1_3_2_44_2","first-page":"abstr 401","article-title":"Week 96 efficacy and safety of long-acting cabotegravir + rilpivirine every 2 months: ATLAS-2M","author":"Jaeger H","year":"2021","unstructured":"Jaeger H, Overton ET, Richmond G, Rizzardini G, Andrade-Villanueva JF, Mngqibisa R, Ocampo HA, Thalme A, Benn PD, Wang Y, Hudson KJ, Margolis DA, Talarico C, Vandermeulen K, Spreen WR. 2021. Week 96 efficacy and safety of long-acting cabotegravir + rilpivirine every 2 months: ATLAS-2M. Abstr Conference on Retroviruses and Opportunistic Infections, abstr 401.","journal-title":"Abstr Conference on Retroviruses and Opportunistic Infections"},{"key":"e_1_3_2_45_2","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0b013e31823df4da"},{"key":"e_1_3_2_46_2","first-page":"111","article-title":"2019 update of the drug resistance mutations in HIV-1","volume":"27","author":"Wensing AM","year":"2019","unstructured":"Wensing AM, Calvez V, Ceccherini-Silberstein F, Charpentier C, G\u00fcnthard HF, Paredes R, Shafer RW, Richman DD. 2019. 2019 update of the drug resistance mutations in HIV-1. Top Antivir Med 27:111\u2013121.","journal-title":"Top Antivir Med"},{"key":"e_1_3_2_47_2","doi-asserted-by":"publisher","DOI":"10.1016\/0022-2836(81)90087-5"},{"key":"e_1_3_2_48_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.44.4.920-928.2000"},{"key":"e_1_3_2_49_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.59.2.284-291.1986"},{"key":"e_1_3_2_50_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.73.7.5577-5585.1999"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/aac.01702-21","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/aac.01702-21","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,15]],"date-time":"2022-03-15T15:03:31Z","timestamp":1647356611000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/aac.01702-21"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,15]]},"references-count":49,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,3,15]]}},"alternative-id":["10.1128\/aac.01702-21"],"URL":"https:\/\/doi.org\/10.1128\/aac.01702-21","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,15]]},"assertion":[{"value":"2021-08-26","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-12-21","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-03-15","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e01702-21"}}